Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours

BACKGROUND: Treatment options for patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP NETs) are still limited. We investigated the antitumour activity and safety profile of pazopanib – a multitarget drug with anti-angiogenic activity in patients with metastatic GEP NETs. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, H K, Choi, J Y, Kim, K-M, Kim, H, Choi, S-H, Park, S H, Park, J O, Lim, H Y, Kang, W K, Lee, J, Park, Y S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776983/
https://www.ncbi.nlm.nih.gov/pubmed/23989950
http://dx.doi.org/10.1038/bjc.2013.470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776983/
https://www.ncbi.nlm.nih.gov/pubmed/23989950
http://dx.doi.org/10.1038/bjc.2013.470

Ejemplares similares